📊 AFJKR Key Takeaways
Is Aimei Health Technology Co., Ltd. (AFJKR) a Good Investment?
Aimei Health is a blank check company with critical financial distress, including negative stockholders' equity of -$3.4M, virtually no liquid cash ($3K), and severe liquidity crisis with current ratio of 0.01x. The company is burning cash with negative operating cash flow of -$521.9K despite reporting positive net income, signaling accounting quality concerns and unsustainable operations.
Aimei Health Technology Co., Ltd. shows very weak fundamentals for an operating business: no reported revenue, negative operating cash flow, a sizable operating loss, and an extremely strained liquidity position. The reported net income appears unsupported by core operations, while negative equity and minimal cash indicate substantial balance sheet and going-concern risk.
Why Buy Aimei Health Technology Co., Ltd. Stock? AFJKR Key Strengths
- Reported net income of $961.7K in latest period
- Total assets of $45.5M provide some asset base
- Relatively low total liabilities of $3.5M compared to assets
- Total liabilities are modest relative to total assets on the surface
- Reported net income was positive in the latest period
- Asset base remains sizable at $45.47M
AFJKR Stock Risks: Aimei Health Technology Co., Ltd. Investment Risks
- Negative stockholders' equity of -$3.4M indicates insolvency
- Critical liquidity crisis with only $3K cash and 0.01x current ratio - immediate solvency risk
- Negative operating cash flow of -$521.9K contradicts positive net income - potential accounting manipulation or non-cash gains
- No revenue reported - business model not operational
- Negative operating income of -$585.2K
- Blank check company status indicates pre-merger/acquisition stage with unproven business model
- Zero insider buying activity signals lack of management confidence
- No revenue base or gross profit makes profitability quality very weak
- Current ratio and quick ratio of 0.01x indicate severe liquidity stress
- Negative stockholders equity and almost no cash materially weaken financial health
Key Metrics to Watch
- Cash position and runway to funding/merger completion
- Operating cash flow sustainability and reconciliation with net income
- Stockholders' equity recovery path and capitalization timeline
- Revenue generation post-acquisition or business combination
- Current ratio improvement and working capital management
- Cash balance and operating cash burn
- Any transition to sustainable revenue and positive operating income
Aimei Health Technology Co., Ltd. (AFJKR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
AFJKR Profit Margin, ROE & Profitability Analysis
AFJKR vs Market Sector: How Aimei Health Technology Co., Ltd. Compares
How Aimei Health Technology Co., Ltd. compares to Market sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aimei Health Technology Co., Ltd. Stock Overvalued? AFJKR Valuation Analysis 2026
Based on fundamental analysis, Aimei Health Technology Co., Ltd. has mixed fundamental signals relative to the Market sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aimei Health Technology Co., Ltd. Balance Sheet: AFJKR Debt, Cash & Liquidity
AFJKR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aimei Health Technology Co., Ltd.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.08 reflects profitable operations.
AFJKR Revenue Growth, EPS Growth & YoY Performance
Aimei Health Technology Co., Ltd. Dividends, Buybacks & Capital Allocation
AFJKR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aimei Health Technology Co., Ltd. (CIK: 0001979005)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AFJKR
What is the AI rating for AFJKR?
Aimei Health Technology Co., Ltd. (AFJKR) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 95% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AFJKR's key strengths?
Claude: Reported net income of $961.7K in latest period. Total assets of $45.5M provide some asset base. ChatGPT: Total liabilities are modest relative to total assets on the surface. Reported net income was positive in the latest period.
What are the risks of investing in AFJKR?
Claude: Negative stockholders' equity of -$3.4M indicates insolvency. Critical liquidity crisis with only $3K cash and 0.01x current ratio - immediate solvency risk. ChatGPT: No revenue base or gross profit makes profitability quality very weak. Current ratio and quick ratio of 0.01x indicate severe liquidity stress.
What is AFJKR's revenue and growth?
Aimei Health Technology Co., Ltd. reported revenue of N/A.
Does AFJKR pay dividends?
Aimei Health Technology Co., Ltd. does not currently pay dividends.
Where can I find AFJKR SEC filings?
Official SEC filings for Aimei Health Technology Co., Ltd. (CIK: 0001979005) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AFJKR's EPS?
Aimei Health Technology Co., Ltd. has a diluted EPS of $0.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AFJKR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Aimei Health Technology Co., Ltd. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AFJKR stock overvalued or undervalued?
Valuation metrics for AFJKR: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AFJKR stock in 2026?
Our dual AI analysis gives Aimei Health Technology Co., Ltd. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AFJKR's free cash flow?
Aimei Health Technology Co., Ltd.'s operating cash flow is $-521.9K, with capital expenditures of N/A.
How does AFJKR compare to other Market stocks?
Vs Default sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.01 (avg: 1.8).